Study of WAL0921 in Patients With Glomerular Kidney Diseases

NCT06466135 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

96

Enrollment

INDUSTRY

Sponsor class

Conditions

Diabetic Nephropathies
Primary Focal Segmental Glomerulosclerosis
Minimal Change Disease
Primary Immunoglobulin A Nephropathy
Primary Membranous Nephropathy

Interventions

DRUG: WAL0921
DRUG: Placebo

Sponsor

Walden Biosciences